Administer IV infusion over 30-120 min. Nosocomial pneumonia, CAP including concurrent bacteremia & complicated skin & skin structure infectionAdult & adolescent (≥12 yr) 600 mg IV every 12 hr for 10-14 days. Childn (birth through 11 yr) 10 mg/kg IV every 8 hr for 10-14 days. Vancomycin-resistant Enterococcus faecium infection including concurrent bacteremiaAdult & adolescent (≥12 yr) 600 mg IV every 12 hr for 10-14 days. Childn (birth through 11 yr) 10 mg/kg IV every 8 hr. AdultInfection due to MRSA 600 mg every 12 hr. Pre-term neonate <7 days 10 mg/kg every 12 hr. May consider 10 mg/kg every 8 hr in neonates w/ sub-optimal clinical response. All neonatal patient should receive 10 mg/kg every 8 hr by 7 days of life.
Not indicated for gm -ve infections. Not to be used for the treatment of patients w/ catheter-related bloodstream infections or catheter-site infections. Treatment >28 days. Discontinue therapy in patients who develop or have worsening myelosuppression; peripheral & optic neuropathy. Clostridium difficile associated diarrhea. Patients w/ uncontrolled HTN, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism. Lactic acidosis. Risk of development of drug-resistant bacteria. History of seizures or w/ risk factors for seizures. Potential hypoglycemic reactions in diabetic patients. Monitor CBC wkly in patients receiving treatment >2wk; those w/ increased hemorrhagic risk; pre-existing myelosuppression; those receiving concomitant drugs that produce bone marrow suppression or drugs w/ tendency to decrease Hb, platelet count or function or those w/ chronic infection who have received previous or concomitant antibiotic therapy. Prompt ophth eval is recommended if visual impairment eg, changes in visual acuity, color vision, blurred vision or visual field defect is experienced. Severe renal & hepatic insufficiency. Pregnancy. Discontinue during lactation. Patient weighing <40 kg. May reversibly impair fertility in male patients.
Sign Out
